Comment on Jungbluth et al, page [167][1] Jungbluth and colleagues have identified 2 cancer testis antigens as potential diagnostic and therapeutic targets in multiple myeloma. Despite the advent of mechanistically diverse agents with important clinical efficacy, multiple myeloma remains an
No takes yet. Share an insight, caveat, or question.
Huff et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: